m4 Award winner RevoBITs impresses in the nationwide selection process of EXIST Research Transfer and receives EUR 1.25 million in funding. With its smart bioprinter, the start-up aims to significantly improve biological reproducibility.
Biotech start-up RevoBITs from Erlangen, winner of the m4 Award 2023, has been selected for the renowned EXIST Research Transfer funding program run by the German Federal Ministry for Economic Affairs and Energy. The award is one of the most prestigious public funding instruments for deep tech start-ups in Germany. Only projects that demonstrate technical excellence, clear value creation prospects, and a high degree of innovation are eligible for this funding.
With the EUR 1.25 million in non-dilutive funding provided, RevoBITs is pushing ahead with the development of the world's first smart bioprinter, which will enable medical research and the pharmaceutical industry to establish and reliably produce meaningful human tissue models. With a new print head technology and integrated quality control, RevoBITs offers the technological basis to reduce animal testing in drug discovery and to provide tissue for transplantation medicine in the long term.
The team plans to implement intelligent hardware and software modules that enable unprecedented biological reproducibility. In addition, the bioprinter's functions are to be validated in specific use cases with pilot customers, and important steps are to be taken on the path from prototype to product and ultimately to market.
In 2023, RevoBITs won the pre-seed competition m4 Award coordinated by BioM. With this award, the Free State of Bavaria supports academic teams with spin-off potential. The m4 Award is presented every two years with 2.5 million euros to five teams to promote spin-offs.